Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome: New Developments in Diagnosis and Treatment

References

• Grob D, Brunner NG, Namba T. The natural course of myasthenia gravis and effect of therapeutic measures. NYAS. 1981;377:652–669.
   PubMed Web of Science ®Google Scholar
• Oosterhuis HJ. The natural course of myasthenia gravis: a long term follow up study. J Neurol Neurosurg Psychiatry. 1989;52(10):1121–1127. PMID: 2795037; PMCID: PMC1031695. doi:10.1136/jnnp.52.10.1121
   PubMed Web of Science ®Google Scholar
• Lazaridis K, Tzartos SJ. Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics. Front Immunol. 2020;11:212. doi:10.3389/fimmu.2020.00212
   PubMed Web of Science ®Google Scholar
• Hughes BW, Kusner LL, Kaminski HJ. Molecular architecture of the neuromuscular junction. Muscle Nerve. 2006;33(4):445–461. PMID: 16228970. doi:10.1002/mus.20440
   PubMed Web of Science ®Google Scholar
• Bacchi S, Kramer P, Chalk C. Autoantibodies to low-density lipoprotein receptor-related protein 4 in double seronegative myasthenia gravis: a systematic review. Can J Neurol Sci. 2018;45:62–67. doi:10.1017/cjn.2017.253
   PubMed Web of Science ®Google Scholar
• Zhang B, Shen C, Bealmear B, et al. Autoantibodies to agrin in myasthenia gravis patients. PLoS One. 2014;9:e91816. doi:10.1371/journal.pone.0091816
   PubMed Web of Science ®Google Scholar
• Gasperi C, Melms A, Schoser B, et al. Anti-agrin autoantibodies in myasthenia gravis. Neurology. 2014;82(22):1976–1983. doi:10.1212/WNL.0000000000000478
   PubMed Web of Science ®Google Scholar
• Yoganathan K, Stevenson A, Tahir A, Sadler R, Radunovic A, Malek N. Bedside and laboratory diagnostic testing in myasthenia. J Neurol. 2022;269(6):3372–3384. PMID: 35142871; PMCID: PMC9119875. doi:10.1007/s00415-022-10986-3
   Web of Science ®Google Scholar
• Skolka M, Lamb CJ, Rubin DI, Klein CJ, Laughlin RS. Electrodiagnostic characteristics suggestive of muscle-specific kinase myasthenia gravis. Neurol Clin Pract. 2022;12(3):211–217. doi:10.1212/CPJ.0000000000001166
   Google Scholar
• Pascuzzi RM. The edrophonium test. Semin Neurol. 2003;23(1):83–88. PMID: 12870109. doi:10.1055/s-2003-40755
   PubMed Web of Science ®Google Scholar
• Giannoccaro MP, Paolucci M, Zenesini C, et al. Comparison of ice pack test and single-fiber EMG diagnostic accuracy in patients referred for myasthenic ptosis. Neurology. 2020;95(13):e1800–e1806. PMID: 32788239. doi:10.1212/WNL.0000000000010619
   PubMed Web of Science ®Google Scholar
• Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol. 1984;15(3):291–298. PMID: 6721451. doi:10.1002/ana.410150316
   PubMed Web of Science ®Google Scholar
• Menon D, Bril V. Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals. Drugs. 2022;82:865–887. doi:10.1007/s40265-022-01726-y
   Web of Science ®Google Scholar
• Tindall RS, Phillips JT, Rollins JA, Wells L, Hall K. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci. 1993;681:539–551. PMID: 8357194. doi:10.1111/j.1749-6632.1993.tb22937.x
   PubMed Web of Science ®Google Scholar
• Sanders DB, Hart IK, Mantegazza R, et al. An international, Phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology. 2008;71(6):400–406. doi:10.1212/01.wnl.0000312374.95186.cc
   PubMed Web of Science ®Google Scholar
• Cahoon WD Jr, Kockler DR. Mycophenolate mofetil treatment of myasthenia gravis. Ann Pharmacother. 2006;40(2):295–298. doi:10.1345/aph.1G501
   Web of Science ®Google Scholar
• Wang L, Zhang S, Xi J, et al. Efficacy and safety of tacrolimus for myasthenia gravis: a systematic review and meta-analysis. J Neurol. 2017;264(11):2191–2200. doi:10.1007/s00415-017-8616-7
   PubMed Web of Science ®Google Scholar
• Yoshikawa H, Kiuchi T, Saida T, Takamori M. Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2011;82(9):970–977. doi:10.1136/jnnp-2011-300148
   PubMed Web of Science ®Google Scholar
• Pasnoor M, He J, Herbelin L, et al. A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. Neurology. 2016;87(1):57–64. doi:10.1212/WNL.0000000000002795
   PubMed Web of Science ®Google Scholar
• Howard JF Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16:976–986. doi:10.1016/S1474-4422(17)30369-1
   PubMed Web of Science ®Google Scholar
• Muppidi S, Utsugisawa K, Benatar M, et al. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019;60:14–24. doi:10.1002/mus.26447
   PubMed Web of Science ®Google Scholar
• Vissing J, Jacob S, Fujita KP, O’Brien F, Howard JF; REGAIN study group. ‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. J Neurol. 2020;267(7):1991–2001. PMID: 32189108; PMCID: PMC7320935. doi:10.1007/s00415-020-09770-y
   PubMed Web of Science ®Google Scholar
• Howard JF, Nowak RJ, Wolfe GI, et al. Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. JAMA Neurol. 2020;77(5):582–592. doi:10.1001/jamaneurol.2019.5125
   PubMed Web of Science ®Google Scholar
• Howard JF, Genge A, Hussain Y, et al. Outcomes from raise: a randomized, placebo-controlled, double-blind, phase 3 trial of zilucoplan in generalized myasthenia gravis. mus mgfa Abstracts; 2022.
   Google Scholar
• Vu T, Meisel A, Mantegazza R, et al. Efficacy and safety of ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG study. Neurology. 2022;98(18 Supplement):791.
   Google Scholar
• Hehir MK, Hobson-Webb LD, Benatar M, et al. Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review. Neurology. 2017;89:1069–1077. doi:10.1212/WNL.0000000000004341
   PubMed Web of Science ®Google Scholar
• Tandan R, Hehir MK 2nd, Waheed W, Howard DB. Rituximab treatment of myasthenia gravis: a systematic review. Muscle Nerve. 2017;56:185–196. doi:10.1002/mus.25597
   PubMed Web of Science ®Google Scholar
• Topakian R, Zimprich F, Iglseder S, et al. High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria. J Neurol. 2019;266:699–706. doi:10.1007/s00415-019-09191-6
   PubMed Web of Science ®Google Scholar
• Di Stefano V, Lupica A, Rispoli MG, Di Muzio A, Brighina F, Rodolico C. Rituximab in AChR subtype of myasthenia gravis: systematic review. J Neurol Neurosurg Psychiatry. 2020;91:392–395. doi:10.1136/jnnp-2019-322606
   Web of Science ®Google Scholar
• Young C, McGill SC. Rituximab for the Treatment of Myasthenia Gravis: A 2021 Update [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2021. Available from https://www.ncbi.nlm.nih.gov/books/NBK571915/. Accessed November 25, 2022.
   Google Scholar
• Howard JF Jr, Bril V, Vu T, et al; ADAPT Investigator Study Group. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526–536. Erratum in: Lancet Neurol. 2021 Aug;20(8):e5.PMID: 34146511. doi:10.1016/S1474-4422(21)00159-9
   PubMed Web of Science ®Google Scholar
• Bril V, Benatar M, Andersen H, et al; MG0002 Investigators. Efficacy and safety of rozanolixizumab in moderate to severe generalized myasthenia gravis: a phase 2 randomized control trial. Neurology. 2021;96(6):e853–e865. PMID: 33219142; PMCID: PMC8105899. doi:10.1212/WNL.0000000000011108
   PubMed Web of Science ®Google Scholar
• Bril V, Druzdz A, Grosskreutz J, et al. Efficacy and safety of rozanolixizumab in patients with generalized myasthenia gravis: a randomized, multicenter, double-blind, placebo-controlled phase 3 study MGFA abstracts. Neurology. 2022;65:S35. doi:10.1002/mus.27540
   Google Scholar
• Usmani A, Kwan L, Wahib-Khalil D, Trivedi J, Nations S, Sarode R. Excellent response to therapeutic plasma exchange in myasthenia gravis patients irrespective of antibody status. J Clin Apher. 2019;34:416–422. doi:10.1002/jca.21694
   Web of Science ®Google Scholar
• Yamada C, Teener JW, Davenport RD, Cooling L. Maintenance plasma exchange treatment for muscle specific kinase antibody positive myasthenia gravis patients. J Clin Apher. 2015;30:314–319. doi:10.1002/jca.21377
   Web of Science ®Google Scholar
• Ortiz-Salas P, Velez-Van-Meerbeke A, Galvis-Gomez CA, Rodriguez QJ. Human immunoglobulin versus plasmapheresis in guillain-barre syndrome and myasthenia gravis: a meta-analysis. J Clin Neuromuscul Dis. 2016;18:1–11. doi:10.1097/CND.0000000000000119
   PubMedGoogle Scholar
• Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87:419–425. doi:10.1212/WNL.0000000000002790
   PubMed Web of Science ®Google Scholar
• Adiao KJB, Espiritu AI, Roque VLA, Reyes J. Efficacy and tolerability of subcutaneously administered immunoglobulin in myasthenia gravis: a systematic review. J Clin Neurosci. 2020;72:316–321.
   Web of Science ®Google Scholar
• Hellmann MA, Mosberg-Galili R, Lotan I, Steiner I. Maintenance IVIg therapy in myasthenia gravis does not affect disease activity. J Neurol Sci. 2014;338:39–42. doi:10.1016/j.jns.2013.10.043
   PubMed Web of Science ®Google Scholar
• Alipour-Faz A, Shojaei M, Peyvandi H, et al. A comparison between IVIG and plasma exchange as preparations before thymectomy in myasthenia gravis patients. Acta Neurol Belg. 2017;117:245–249. doi:10.1007/s13760-016-0689-z
   PubMed Web of Science ®Google Scholar
• Rahbek MA, Mikkelsen EE, Overgaard K, Vinge L, Andersen H, Dalgas U. Exercise in myasthenia gravis: a feasibility study of aerobic and resistance training. Muscle Nerve. 2017;56:700–709. doi:10.1002/mus.25552
   PubMed Web of Science ®Google Scholar
• McQuillen MP, Leone MG. A treatment carol: thymectomy revisited. Neurology. 1977;27:1103–1106. doi:10.1212/WNL.27.12.1103
   Web of Science ®Google Scholar
• Wolfe GI, Kaminski HJ, Aban IB, et al. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med. 2016;375:511–522. doi:10.1056/NEJMoa1602489
   PubMed Web of Science ®Google Scholar
• Wolfe GI, Kaminski HJ, Aban IB, et al. Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurol. 2019;18:259–268. doi:10.1016/S1474-4422(18)30392-2
   PubMed Web of Science ®Google Scholar
• Gronseth GS, Barohn R, Narayanaswami P. Practice advisory: thymectomy for myasthenia gravis (practice parameter update): report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology. 2020;94:705–709. doi:10.1212/WNL.0000000000009294
   Web of Science ®Google Scholar
• Zhu K, Li J, Huang X, et al. Thymectomy is a beneficial therapy for patients with non-thymomatous ocular myasthenia gravis: a systematic review and meta-analysis. Neurol Sci. 2017;38:1753–1760. doi:10.1007/s10072-017-3058-7
   PubMed Web of Science ®Google Scholar
• Mehrizi M, Fontem RF, Gearhart TR, Pascuzzi RM. Medications and myasthenia gravis (a reference for health care professionals) prepared for the myasthenia gravis foundation of America; 2012. Available from: www.myasthenia.org. Accessed November 25, 2022.
   Google Scholar
• Mehrizi M, Pascuzzi RM. Complications of radiologic contrast in patients with myasthenia gravis. Muscle Nerve. 2014;50:443–444. doi:10.1002/mus.24254
   Web of Science ®Google Scholar
• Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann Intern Med. 2018;168:121–130. doi:10.7326/M17-2073
   PubMed Web of Science ®Google Scholar
• Safa H, Johnson DH, Trinh VA, et al. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019;7:319. doi:10.1186/s40425-019-0774-y
   PubMed Web of Science ®Google Scholar
• Kochhar PK, Schumacher RE, Sarkar S. Transient neonatal myasthenia gravis: refining risk estimate for infants born to women with myasthenia gravis. J Perinatol. 2021;41:2279–2283. doi:10.1038/s41372-021-00970
   Web of Science ®Google Scholar
• Vanhaesebrouck AE, Beeson D. The congenital myasthenic syndromes: expanding genetic and phenotypic spectrums and refining treatment strategies. Curr Opin Neurol. 2019;32:696–703. doi:10.1097/WCO.0000000000000736
   PubMed Web of Science ®Google Scholar
• Burns TM, Russell JA, LaChance DH, Jones HR. Oculobulbar involvement is typical with Lambert-Eaton myasthenic syndrome. Ann Neurol. 2003;53:270–273. doi:10.1002/ana.10477
   PubMed Web of Science ®Google Scholar
• Young JD, Leavitt JA. Lambert-Eaton myasthenic syndrome: ocular signs and symptoms. J Neuroophthalmol. 2016;36:20–22. doi:10.1097/WNO.0000000000000258
   Web of Science ®Google Scholar
• Kennelly KD, Dodick DW, Pascuzzi RM, et al. Neuronal autoantibodies and paraneoplastic neurological syndromes associated with extrapulmonary small cell carsinoma. Neurology. 1997;48:A31–A32.
   Web of Science ®Google Scholar
• Hong BY, An HJ, Lim SH. Long-Standing Lambert–Eaton myasthenic syndrome caused by undetectable small-cell lung cancer: why we should follow-up LEMS. Diagnostics. 2022;12:1542. doi:10.3390/diagnostics12071542
   Web of Science ®Google Scholar
• Sabater L, Titulaer M, Saiz A, Verschuuren J, Gure AO, Graus F. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology. 2008;70:924–928. doi:10.1212/01.wnl.0000281663.81079.24
   PubMed Web of Science ®Google Scholar
• Kesner VG, Oh SJ, Dimachkie MM, Barohn RJ. Lambert-Eaton myasthenic syndrome. Neurol Clin. 2018;36:379–394. doi:10.1016/j.ncl.2018.01.008
   PubMed Web of Science ®Google Scholar
• Maddison P, Gozzard P, Grainge MJ, Lang B. Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology. 2017;88:1334–1339. doi:10.1212/WNL.0000000000003794
   PubMed Web of Science ®Google Scholar
• McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med. 1989;321:1567–1571. doi:10.1056/NEJM198912073212303
   PubMed Web of Science ®Google Scholar
• Oh SJ, Shcherbakova N, Kostera-Pruszczyk A, et al. Amifampridine phosphate (Firdapse((R))) is effective and safe in a phase 3 clinical trial in LEMS. Muscle Nerve. 2016;53:717–725. doi:10.1002/mus.25070
   PubMed Web of Science ®Google Scholar
• Sanders DB, Juel VC, Harati Y, et al. 3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia. Muscle Nerve. 2018;57:561–568. doi:10.1002/mus.26052
   PubMed Web of Science ®Google Scholar
• Anwar A, Saleem S, Ahmed MF, Ashraf S, Ashraf S. Recent advances and therapeutic options in Lambert-Eaton myasthenic syndrome. Cureus. 2019;11(8):e5450. PMID: 31637147; PMCID: PMC6799875. doi:10.7759/cureus.5450
   Web of Science ®Google Scholar
• Meisel A, Sieb JP, Le Masson G, et al. The European Lambert–Eaton myasthenic syndrome registry: long-term outcomes following symptomatic treatment. Neurol Ther. 2022;11(3):1071–1083. doi:10.1007/s40120-022-00354-8
   Web of Science ®Google Scholar
• Johns TR, editor. Myasthenia gravis. In: Seminars in Neurology. Vol. 2. StatPearls [Internet]; 1982:3. doi:10.1055/s-002-11126
   Google Scholar
• Nowak RJ, Coffey CS, Goldstein JM, et al. (29a) rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG study. Neurology. 2022;98(4):e376–e389. doi:10.1212/WNL.0000000000013121
   Web of Science ®Google Scholar
• Jaretzki AI, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis recommendations for clinical research standards task force of the medical scientific advisory board of the myasthenia gravis foundation of America. Neurology. 2000;55(1):16–23. doi:10.1212/WNL.55.1.16
   PubMed Web of Science ®Google Scholar
• Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci. 1998;841:769–772. doi:10.1111/j.1749-6632.1998.tb11015.x
   PubMed Web of Science ®Google Scholar
• Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology. 1999;52:1487–1489. doi:10.1212/WNL.52.7.1487
   PubMed Web of Science ®Google Scholar
• Burns TM, Conaway MR, Cutter GR, Sanders DB. Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis. Muscle Nerve. 2008;38(2):957–963. doi:10.1002/mus.21053
   PubMed Web of Science ®Google Scholar
• Burns TM, Sadjadi R, Utsugisawa K, et al. International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r. Muscle Nerve. 2016;54(6):1015–1022. doi:10.1002/mus.25198
   PubMed Web of Science ®Google Scholar
• Burns TM, Conaway MR, Cutter GR, Sanders DB. Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite. Muscle Nerve. 2008;38(6):1553–1562. doi:10.1002/mus.21185
   PubMed Web of Science ®Google Scholar
• Burns TM, Conaway M, Sanders DB; MG Composite and MG-QOL15 Study Group. The MG composite: a valid and reliable outcome measure for myasthenia gravis. Neurology. 2010;74(18):1434–1440. doi:10.1212/WNL.0b013e3181dc1b1e
   PubMed Web of Science ®Google Scholar
• Thomsen JLS, Andersen H. Outcome measures in clinical trials of patients with myasthenia gravis. Front Neurol. 2020;11:596382. PMID: 33424747; PMCID: PMC7793650. doi:10.3389/fneur.2020.596382
   PubMed Web of Science ®Google Scholar